Trial Search Results

Management of the PDA Trial

Estimate the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

NICHD Neonatal Research Network

Stanford Investigator(s):

Intervention(s):

  • Other: Active Treatment
  • Other: Expectant Management

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Postnatal age 48 hours -21 days

   - Infant 22 0/7 to 28 6/7 weeks gestation at birth

   - sPDA, as defined as:

      1. Mild, Moderate, or Severe Clinical Criteria with Small or Moderate size PDA on
      echocardiogram

      2. Mild or Moderate Clinical Criteria with Large PDA on echocardiogram

Exclusion Criteria:

   - Cardiopulmonary compromise

   - Known congenital heart disease (besides atrial septal defect or ventricular septal
   defect)

   - Known pulmonary malformation (e.g. congenital lobar emphysema, congenital pulmonary
   adenomatous malformation)

   - Any condition which, in the opinion of the investigator, would preclude enrollment

Ages Eligible for Study

N/A - 21 Days

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Krisa P. Van Meurs, MD
650-723-5711
Recruiting